Therefore, the presence of auto- and alloantibodies, elevated plasma levels of B-cell activation factor (BAFF), a cytokine of the tumor necrosis family, and an accumulation of CD19+CD21low B-cells serve as biomarkers for GvHD. Here, TNFSF13B is linked to graft versus host disease.